{"id":"candida-antigen","safety":{"commonSideEffects":[{"rate":null,"effect":"Local induration or erythema at injection site"},{"rate":null,"effect":"Systemic hypersensitivity reactions"}]},"_chembl":null,"_dailymed":{"setId":"4254e4c8-4a44-4766-8caf-61c65dc3267c","title":"CANDIN (CANDIDA ALBICANS SKIN TEST ANTIGEN) INJECTION, SOLUTION [NIELSEN BIOSCIENCES, INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The antigen is injected intradermally, and a positive reaction (induration at the injection site) indicates intact T-cell mediated immunity. It is used clinically as an immunocompetence test to evaluate whether a patient's immune system can mount a normal delayed hypersensitivity response, helping to assess immunosuppression or immune deficiency.","oneSentence":"Candida Antigen is a diagnostic skin test antigen derived from Candida albicans that elicits a delayed-type hypersensitivity reaction to assess cell-mediated immune function.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:04:55.706Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Assessment of cell-mediated immunity and immunocompetence in immunocompromised patients"},{"name":"Evaluation of delayed-type hypersensitivity response"}]},"trialDetails":[{"nctId":"NCT07422155","phase":"NA","title":"Non-Conventional Microbiological Methods in the Diagnosis of Candidemia","status":"COMPLETED","sponsor":"Institute of Oncology Ljubljana","startDate":"2015-01","conditions":"Candidemia, Invasive Candidiasis","enrollment":2},{"nctId":"NCT07329907","phase":"PHASE2","title":"Combination Therapy for Warts: Candida Antigen vs. Topical Keratolytic","status":"COMPLETED","sponsor":"Benha University","startDate":"2023-12-01","conditions":"Warts, Human Papilloma Virus (HPV)","enrollment":126},{"nctId":"NCT01322698","phase":"","title":"Staging Candidiasis in ICU Patients","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2011-10","conditions":"Candidiasis","enrollment":422},{"nctId":"NCT05889845","phase":"PHASE3","title":"Candin for the Treatment of Common Warts","status":"COMPLETED","sponsor":"Nielsen BioSciences, Inc.","startDate":"2025-01-22","conditions":"Common Warts (Verruca Vulgaris)","enrollment":330},{"nctId":"NCT06720467","phase":"PHASE2","title":"Immunotherapy in Eyelid Viral Papilloma","status":"COMPLETED","sponsor":"Zagazig University","startDate":"2024-06-11","conditions":"Eye Infections","enrollment":22},{"nctId":"NCT03704766","phase":"NA","title":"Alpha-Defensin and Synovial Proteins to Improve Detection of Pediatric Septic Arthritis","status":"RECRUITING","sponsor":"Hospital for Special Surgery, New York","startDate":"2016-06-28","conditions":"Joint Infection, Infection of Hip Joint (Disorder), Infection of Shoulder Joint","enrollment":442},{"nctId":"NCT05291845","phase":"PHASE2","title":"Candida Antigen and Bivalent HPV Vaccine in the Treatment of Multiple Warts","status":"RECRUITING","sponsor":"Zagazig University","startDate":"2022-04-03","conditions":"Warts, Human Papilloma Virus","enrollment":162},{"nctId":"NCT02889159","phase":"PHASE1","title":"Immunologic Profile of Chronically Photodamaged Skin","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2016-06-06","conditions":"Photoaged Skin, Normal Skin","enrollment":40},{"nctId":"NCT03953196","phase":"EARLY_PHASE1","title":"A Study Exploring the Use of Vaccine and Antigen Challenges for Immune Monitoring in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2019-04-08","conditions":"Healthy","enrollment":48},{"nctId":"NCT06749665","phase":"NA","title":"Sclerotherapy and Candida Antigen in Treatment of Common Warts","status":"NOT_YET_RECRUITING","sponsor":"Sohag University","startDate":"2024-12-20","conditions":"Common Wart","enrollment":75},{"nctId":"NCT03421002","phase":"PHASE2","title":"Determination of Levels of Micafungin in Neonates Suffering From Systemic Candidiasis and/or Candida Meningitis","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2015-05-30","conditions":"Candidiasis, Systemic, Candida Meningitis","enrollment":35},{"nctId":"NCT05216510","phase":"PHASE1","title":"Assessment of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 Peptide Antigens","status":"TERMINATED","sponsor":"Tonix Pharmaceuticals, Inc.","startDate":"2022-01-07","conditions":"Detection of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 in Individuals Exposed to SARS-CoV-2","enrollment":9},{"nctId":"NCT06564805","phase":"NA","title":"Clinical Trial on the Efficacy of Intralesional Triamcinolone Versus Candida Albicans Antigen in Treating Alopecia Areata","status":"RECRUITING","sponsor":"Universidad Autonoma de Nuevo Leon","startDate":"2024-08-20","conditions":"Alopecia Areata","enrollment":30},{"nctId":"NCT05079711","phase":"","title":"Comparative Performance of a Vaginal Yeast Test","status":"RECRUITING","sponsor":"Uniformed Services University of the Health Sciences","startDate":"2022-03-18","conditions":"Vulvovaginal Candidiasis","enrollment":1200},{"nctId":"NCT05652998","phase":"PHASE4","title":"Comparison Between Intralesional Injection of Plasma Rich Platelets and Candida Antigen in Plane Warts","status":"UNKNOWN","sponsor":"South Valley University","startDate":"2021-10-15","conditions":"Plane Wart","enrollment":30},{"nctId":"NCT05429151","phase":"PHASE4","title":"Intralesional Injection of Acyclovir Versus Candida Antigen in Treatment of Plantar Warts","status":"UNKNOWN","sponsor":"Sohag University","startDate":"2022-06-13","conditions":"Acyclovir and Candida Antigen in Treatment of Plantar Wart","enrollment":40},{"nctId":"NCT05254561","phase":"PHASE2, PHASE3","title":"Triple Antigen vs Monoantigen Immunotherapy for Warts","status":"COMPLETED","sponsor":"Zagazig University","startDate":"2020-11-20","conditions":"Triple Intralesional Immunotherapy Combination in Multiple Recalcitrant Warts","enrollment":160},{"nctId":"NCT01757392","phase":"PHASE2","title":"Candin Safety & Efficacy Study for the Treatment of Warts","status":"COMPLETED","sponsor":"Nielsen BioSciences, Inc.","startDate":"2012-09","conditions":"Warts, Human Papilloma Virus","enrollment":39},{"nctId":"NCT02996448","phase":"PHASE2","title":"Safety, Tolerability, and Immunogenicity of One Dose of NDV 3A Vaccine in People With STAT3-Mutated Hyper-IgE Syndrome","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-11-17","conditions":"Autosomal-dominant Hyper-IgE Syndrome","enrollment":3},{"nctId":"NCT04399577","phase":"PHASE2","title":"Complement Component 3c and Tumor Necrosis Factor-α in Patients With Human Papillomavirus-Induced Cutaneous Warts","status":"COMPLETED","sponsor":"Zagazig University","startDate":"2017-07-01","conditions":"Warts","enrollment":39},{"nctId":"NCT02393417","phase":"PHASE2","title":"Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris)","status":"COMPLETED","sponsor":"Nielsen BioSciences, Inc.","startDate":"2015-03","conditions":"Warts","enrollment":243},{"nctId":"NCT03853785","phase":"PHASE3","title":"Efficacy of Intralesional MMR Vaccine,Intralesional Candidal Antigen&Topical Podophyllin in Treatment of Genital Warts","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2020-02","conditions":"Condylomata Acuminata","enrollment":45},{"nctId":"NCT03158168","phase":"PHASE3","title":"Intralesional Candidal Antigen Versus Intralesional Zinc Sulphate in Treatment of Cutaneous Warts","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2018-03-01","conditions":"Warts","enrollment":70},{"nctId":"NCT01926028","phase":"PHASE1, PHASE2","title":"Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis","status":"COMPLETED","sponsor":"NovaDigm Therapeutics, Inc.","startDate":"2013-07","conditions":"Vulvovaginal Candidiasis","enrollment":188},{"nctId":"NCT02521610","phase":"PHASE1","title":"A Multiple Ascending-Dose Study of RG7625 in Healthy Volunteers","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-08","conditions":"Healthy Volunteer","enrollment":33},{"nctId":"NCT00953927","phase":"PHASE2","title":"A Study of MVA85A in Healthy Infants","status":"COMPLETED","sponsor":"Aeras","startDate":"2009-07","conditions":"Tuberculosis","enrollment":2797},{"nctId":"NCT01151189","phase":"PHASE2","title":"Efficacy Against TB Disease, Safety, and Immunogenicity of MVA85A/AERAS-485 in HIV-Infected Adults (C-030-485)","status":"COMPLETED","sponsor":"Aeras","startDate":"2011-07","conditions":"Tuberculosis, HIV Infections","enrollment":650},{"nctId":"NCT01370837","phase":"NA","title":"Neurogenic Inflammation in Diabetes","status":"COMPLETED","sponsor":"Maastricht University Medical Center","startDate":"2012-05","conditions":"Diabetes Mellitus, Polyneuropathies, Arthropathy, Neurogenic","enrollment":41},{"nctId":"NCT00006113","phase":"PHASE2","title":"Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma","status":"TERMINATED","sponsor":"University of Southern California","startDate":"1999-06","conditions":"Melanoma (Skin)","enrollment":25},{"nctId":"NCT01067131","phase":"PHASE1","title":"Safety and Immunogenicity Study of a Virosomal Vaccine Against Recurrent Vulvovaginal Candida Infection","status":"COMPLETED","sponsor":"Pevion Biotech Ltd","startDate":"2010-03","conditions":"Recurrent Vulvovaginal Candidiasis","enrollment":48},{"nctId":"NCT00569231","phase":"PHASE1","title":"Study With Candida Antigen for Treatment of Warts","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2007-02","conditions":"Warts, HPV","enrollment":18}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"DERMATITIS PSORIASIFORM"},{"count":1,"reaction":"DRUG INEFFECTIVE FOR UNAPPROVED INDICATION"},{"count":1,"reaction":"EPIDERMODYSPLASIA VERRUCIFORMIS"},{"count":1,"reaction":"GUTTATE PSORIASIS"},{"count":1,"reaction":"HAEMORRHAGE"},{"count":1,"reaction":"OFF LABEL USE"},{"count":1,"reaction":"PAIN"},{"count":1,"reaction":"PAPILLOMA VIRAL INFECTION"},{"count":1,"reaction":"RENAL IMPAIRMENT"},{"count":1,"reaction":"THERAPY NON-RESPONDER"}],"_approvalHistory":[],"publicationCount":369,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Candin"],"phase":"marketed","status":"active","brandName":"Candida Antigen","genericName":"Candida Antigen","companyName":"University of Arkansas","companyId":"university-of-arkansas","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Candida Antigen is a diagnostic skin test antigen derived from Candida albicans that elicits a delayed-type hypersensitivity reaction to assess cell-mediated immune function. Used for Assessment of cell-mediated immunity and immunocompetence in immunocompromised patients, Evaluation of delayed-type hypersensitivity response.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}